Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

This study is currently recruiting participants.
Verified January 2013 by Yale University
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Terri Parker, Yale University
ClinicalTrials.gov Identifier:
NCT01465230
First received: October 28, 2011
Last updated: January 14, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2016
  Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)